eXoZymes (NASDAQ:EXOZ) Trading Up 0.7% – What’s Next?

eXoZymes Inc. (NASDAQ:EXOZ)’s stock price shot up 0.7% during mid-day trading on Thursday . The stock traded as high as $6.54 and last traded at $6.2150. 8,331 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 5,174 shares. The stock had previously closed at $6.17.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of eXoZymes in a research report on Wednesday, August 26th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, eXoZymes currently has an average rating of “Sell”.

eXoZymes Stock Performance

The firm has a market cap of $61.25 million, a price-to-earnings ratio of -5.55 and a beta of 3.14. The company has a quick ratio of 3.81, a current ratio of 3.81 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $6.12 and a 200 day moving average of $7.90.

eXoZymes (NASDAQ:EXOZ) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.33) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in eXoZymes stock. BlackRock Inc. bought a new position in eXoZymes Inc. (NASDAQ:EXOZ) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,610 shares of the company’s stock, valued at approximately $81,000. BlackRock Inc. owned about 0.10% of eXoZymes as of its most recent filing with the Securities and Exchange Commission.

eXoZymes Company Profile

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.